Adaptimmune Therapeutics Plc Net Asset Quality Index
Adaptimmune Therapeutics Plc net asset quality index. Adaptimmune Therapeutics Plc (ADAP) has a Net Asset Quality Index of -54.3% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $130.63 Million minus total liabilities of $201.59 Million yields net assets of $-70.96 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Adaptimmune Therapeutics Plc shareholders equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Adaptimmune Therapeutics Plc (2011–2024)
Net asset quality index of Adaptimmune Therapeutics Plc from 2011 to 2024. This chart shows how Adaptimmune Therapeutics Plc's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of June 2025, the index stands at -54.3%, representing net assets of $-70.96 Million against total assets of $130.63 Million USD. Check ADAP strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Adaptimmune Therapeutics Plc Net Asset Quality Index by Year (2011–2024)
Adaptimmune Therapeutics Plc net asset quality index by year from 2011 to 2024. The table below presents the year-by-year Net Asset Quality Index for Adaptimmune Therapeutics Plc from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see ADAP company net worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 4.8% | $11.85 Million | $245.96 Million | $234.11 Million | ▼ -9.2 pp |
| 2023 | 14.0% | $39.51 Million | $282.62 Million | $243.10 Million | ▼ -10.9 pp |
| 2022 | 24.9% | $81.88 Million | $328.92 Million | $247.04 Million | ▼ -19.0 pp |
| 2021 | 43.9% | $205.96 Million | $469.55 Million | $263.58 Million | ▼ -31.8 pp |
| 2020 | 75.6% | $341.23 Million | $451.14 Million | $109.92 Million | ▲ +7.5 pp |
| 2019 | 68.1% | $123.64 Million | $181.54 Million | $57.91 Million | ▼ -21.1 pp |
| 2018 | 89.2% | $246.88 Million | $276.74 Million | $29.85 Million | ▲ +17.0 pp |
| 2017 | 72.2% | $202.98 Million | $281.15 Million | $78.16 Million | ▲ +1.4 pp |
| 2016 | 70.8% | $166.14 Million | $234.51 Million | $68.37 Million | ▼ -15.5 pp |
| 2015 | 86.3% | $259.61 Million | $300.68 Million | $41.07 Million | ▲ +0.0 pp |
| 2014 | 86.3% | $259.61 Million | $300.68 Million | $41.07 Million | ▲ +82.0 pp |
| 2013 | 4.3% | $2.41 Million | $55.52 Million | $53.11 Million | ▲ +123.4 pp |
| 2012 | -119.1% | $-2.16 Million | $1.81 Million | $3.97 Million | ▼ -115.9 pp |
| 2011 | -3.2% | $-125.66K | $3.96 Million | $4.09 Million | — |